{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T14:02:50Z","timestamp":1747922570647},"reference-count":38,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,8,1]]},"DOI":"10.5551\/jat.63752","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T22:22:16Z","timestamp":1665699736000},"page":"871-883","source":"Crossref","is-referenced-by-count":2,"title":["Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.5551","volume":"30","author":[{"given":"Tomoyo","family":"Hara","sequence":"first","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Uemoto","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoe","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Otoda","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuro","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Bioregulatory Sciences, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Honda","sequence":"additional","affiliation":[{"name":"Minami Municipal National Insurance Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Tokushima University Graduate School of Biomedical Sciences"},{"name":"Kondo Naika Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[{"name":"Kondo Naika Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Anan Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehide","family":"Matsuhisa","sequence":"additional","affiliation":[{"name":"Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Aihara","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences"},{"name":"Anan Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Fan JG and Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol, 2009; 50: 204-210","DOI":"10.1016\/j.jhep.2008.10.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Fan JG, Li F, Cai XB, Peng YD, Ao QH and Gao Y: The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol, 2007; 22: 663-668","DOI":"10.1111\/j.1440-1746.2007.04892.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J and Ida K: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med, 2005; 143: 722-728","DOI":"10.7326\/0003-4819-143-10-200511150-00009"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Targher G, Day CP and Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med, 2010; 363: 1341-1350","DOI":"10.1056\/NEJMra0912063"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Maurantonio M, Ballestri S, Odoardi MR, Lonardo A and Loria P: Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res, 2011; 42: 337-353","DOI":"10.1016\/j.arcmed.2011.08.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM and Zafarmand MH: Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int, 2021; 41: 261-270","DOI":"10.1111\/liv.14669"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ and Nash Clinical Research N: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2009; 7: 1104-1112","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) McPherson S, Stewart SF, Henderson E, Burt AD and Day CP: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010; 59: 1265-1269","DOI":"10.1136\/gut.2010.216077"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T and Japan Study Group of Nonalcoholic Fatty Liver D: Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol, 2012; 12: 2","DOI":"10.1186\/1471-230X-12-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM and Day CP: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007; 45: 846-854","DOI":"10.1002\/hep.21496"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003; 38: 518-526","DOI":"10.1053\/jhep.2003.50346"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N and Cusi K: Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care, 2021; 44: 399-406","DOI":"10.2337\/dc20-1997"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M and Ghali P: Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One, 2015; 10: e0128774","DOI":"10.1371\/journal.pone.0128774"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J and Goodman Z: The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019; 70: 1913-1927","DOI":"10.1002\/hep.30664"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Popovic M, Smiljanic K, Dobutovic B, Syrovets T, Simmet T and Isenovic ER: Thrombin and vascular inflammation. Mol Cell Biochem, 2012; 359: 301-313","DOI":"10.1007\/s11010-011-1024-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, Daita K, Sanyal AJ and Lisman T: Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol, 2016; 65: 980-987","DOI":"10.1016\/j.jhep.2016.06.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, Bertelli C, Valenti L and Fargion S: Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol, 2014; 61: 148-154","DOI":"10.1016\/j.jhep.2014.03.013"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kassel KM, Owens AP, 3rd, Rockwell CE, Sullivan BP, Wang R, Tawfik O, Li G, Guo GL, Mackman N and Luyendyk JP: Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. Am J Pathol, 2011; 179: 2278-2289","DOI":"10.1016\/j.ajpath.2011.07.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Aihara K: Heparin cofactor II attenuates vascular remodeling in humans and mice. Circ J, 2010; 74: 1518-1523","DOI":"10.1253\/circj.CJ-10-0577"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, Tamura K and Matsumoto T: High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation, 2004; 109: 481-486","DOI":"10.1161\/01.CIR.0000109695.39671.37"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase T, Kondo A and Matsumoto T: Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation, 2004; 109: 2761-2765","DOI":"10.1161\/01.CIR.0000129968.46095.F3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Aihara K, Azuma H, Akaike M, Ikeda Y, Sata M, Takamori N, Yagi S, Iwase T, Sumitomo Y, Kawano H, Yamada T, Fukuda T, Matsumoto T, Sekine K, Sato T, Nakamichi Y, Yamamoto Y, Yoshimura K, Watanabe T, Nakamura T, Oomizu A, Tsukada M, Hayashi H, Sudo T, Kato S and Matsumoto T: Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest, 2007; 117: 1514-1526","DOI":"10.1172\/JCI27095"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Aihara K, Azuma H, Akaike M, Kurobe H, Takamori N, Ikeda Y, Sumitomo Y, Yoshida S, Yagi S, Iwase T, Ishikawa K, Sata M, Kitagawa T and Matsumoto T: Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors. J Atheroscler Thromb, 2009; 16: 127-134","DOI":"10.5551\/jat.E695"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Vicente CP, He L and Tollefsen DM: Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood, 2007; 110: 4261-4267","DOI":"10.1182\/blood-2007-04-086611"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Hara T, Uemoto R, Sekine A, Mitsui Y, Masuda S, Kurahashi K, Yoshida S, Otoda T, Yuasa T, Kuroda A, Ikeda Y, Endo I, Honda S, Yoshimoto K, Kondo A, Tamaki T, Matsumoto T, Matsuhisa M, Abe M and Aihara KI: Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes. J Diabetes Investig, 2021; 12: 2172-2182","DOI":"10.1111\/jdi.13602"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kurahashi K, Inoue S, Yoshida S, Ikeda Y, Morimoto K, Uemoto R, Ishikawa K, Kondo T, Yuasa T, Endo I, Miyake M, Oyadomari S, Matsumoto T, Abe M, Sakaue H and Aihara KI: The Role of Heparin Cofactor in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice. J Atheroscler Thromb, 2017; 24: 1215-1230","DOI":"10.5551\/jat.37739"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) American Diabetes A: 2. Classification and Diagnosis of Diabetes. Diabetes Care, 2016; 39 Suppl 1: S13-22","DOI":"10.2337\/dc16-S005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Friedman SL, Neuschwander-Tetri BA, Rinella M and Sanyal AJ: Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018; 24: 908-922","DOI":"10.1038\/s41591-018-0104-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J and Bugianesi E: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018; 15: 11-20","DOI":"10.1038\/nrgastro.2017.109"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ioannou GN: Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol, 2021; 75: 1476-1484","DOI":"10.1016\/j.jhep.2021.08.012"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Yagi N, Komiya I, Arai K, Oishi M, Fukumoto Y, Shirabe S, Yokoyama H, Yamazaki K, Sugimoto H and Maegawa H: Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists\u2019 prescribing patterns from 2002 to 2019 (JDDM61). J Diabetes Investig, 2022; 13: 65-73","DOI":"10.1111\/jdi.13621"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, Van Marck E, Staels B, Michielsen P and Van Gaal L: Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2014; 59: 121-129","DOI":"10.1002\/hep.26510"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Fritsch P, Kleber M, Rosenkranz A, Fritsch M, Muntean W, Mangge H and Reinehr T: Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis, 2010; 212: 650-655","DOI":"10.1016\/j.atherosclerosis.2010.06.028"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Kopec AK, Joshi N, Towery KL, Kassel KM, Sullivan BP, Flick MJ and Luyendyk JP: Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther, 2014; 351: 288-297","DOI":"10.1124\/jpet.114.218545"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Mihara M, Aihara K, Ikeda Y, Yoshida S, Kinouchi M, Kurahashi K, Fujinaka Y, Akaike M and Matsumoto T: Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db\/db mice. Endocrinology, 2010; 151: 513-519","DOI":"10.1210\/en.2009-0661"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Ikeda Y, Aihara K, Yoshida S, Iwase T, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Tomita S, Tsuchiya K, Sata M, Akaike M, Kato S, Matsumoto T and Tamaki T: Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway. J Biol Chem, 2012; 287: 34256-34263","DOI":"10.1074\/jbc.M112.353532"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Sumitomo-Ueda Y, Aihara K, Ise T, Yoshida S, Ikeda Y, Uemoto R, Yagi S, Iwase T, Ishikawa K, Hirata Y, Akaike M, Sata M, Kato S and Matsumoto T: Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice. Hypertension, 2010; 56: 430-436","DOI":"10.1161\/HYPERTENSIONAHA.110.152207"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Ise T, Aihara K, Sumitomo-Ueda Y, Yoshida S, Ikeda Y, Yagi S, Iwase T, Yamada H, Akaike M, Sata M and Matsumoto T: Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. Hypertens Res, 2011; 34: 225-231","DOI":"10.1038\/hr.2010.211"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/8\/30_63752\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:53:12Z","timestamp":1715575992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/8\/30_63752\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63752","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"article-number":"63752"}}